Follow the people · Insider
Heidy King-Jones
Heidy King-Jones files insider transactions with the SEC as an officer of Spyre Therapeutics (SYRE). We hold 2 disclosed purchases and sales filed since 20 December 2019, 2 of them in the last 90 days.
- Files forSYRE
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure3 September 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 February 2024 — 2 September 2026Officer · Spyre Therapeutics (SYRE)13 Form 4 lines · source: SEC Form 4
- Filed 1 September 2023 — 1 September 2023Officer · Aeglea BioTherapeutics (AGLE)1 Form 4 line · source: SEC Form 4
- Filed 3 August 2020 — 27 April 2023Chief Legal Officer · Provention Bio (PRVB)11 Form 4 lines · source: SEC Form 4
- Filed 18 December 2019 — 18 December 2019General Counsel, SVP Legal · Axcella Health (AXLA)1 Form 4 line · source: SEC Form 4
Everything they disclosed
26 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 27,999 shares of Spyre TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- ▼ sold on the open market 4,845 shares of Spyre TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- ▼ sold on the open market 16,548 shares of Spyre TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- ▼ sold on the open market 6,206 shares of Spyre TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- ▼ sold on the open market 400 shares of Spyre TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- exercised options over 400 shares of Spyre TherapeuticsSEC Form 43 September 2026Common Stock · traded 2 September 2026 · filed 3 September 2026
- ▼ sold on the open market 400 shares of Spyre TherapeuticsSEC Form 43 September 2026Common Stock · traded 2 September 2026 · filed 3 September 2026
- exercised options over 27,999 shares of Spyre Therapeutics (a derivative holding)SEC Form 43 September 2026Stock Option (Right to Buy) · traded 1 September 2026 · filed 3 September 2026
- exercised options over 400 shares of Spyre Therapeutics (a derivative holding)SEC Form 43 September 2026Stock Option (Right to Buy) · traded 2 September 2026 · filed 3 September 2026
- was granted 140,000 shares of Spyre Therapeutics (a derivative holding)SEC Form 413 January 2026Stock Option (Right to Buy) · traded 9 January 2026 · filed 13 January 2026
- was granted 140,000 shares of Spyre Therapeutics (a derivative holding)SEC Form 413 January 2026Stock Option (Right to Buy) · traded 9 January 2026 · filed 13 January 2026
- was granted 95,500 shares of Spyre Therapeutics (a derivative holding)SEC Form 417 January 2025Stock Option (Right to Buy) · traded 15 January 2025 · filed 17 January 2025
- was granted 63,000 shares of Spyre Therapeutics (a derivative holding)SEC Form 42 February 2024Stock Option (Right to Buy) · traded 1 February 2024 · filed 2 February 2024
- was granted 13,495,255 shares of Aeglea BioTherapeutics (a derivative holding)SEC Form 45 September 2023Stock Option (Right to Buy) · traded 1 September 2023 · filed 5 September 2023
- returned to the issuer 300,000 shares of Provention Bio (a derivative holding)SEC Form 427 April 2023Option to Purchase Common Stock · traded 27 April 2023 · filed 27 April 2023
- returned to the issuer 139,500 shares of Provention Bio (a derivative holding)SEC Form 427 April 2023Option to Purchase Common Stock · traded 27 April 2023 · filed 27 April 2023
- returned to the issuer 145,000 shares of Provention Bio (a derivative holding)SEC Form 427 April 2023Option to Purchase Common Stock · traded 27 April 2023 · filed 27 April 2023
- returned to the issuer 200,000 shares of Provention Bio (a derivative holding)SEC Form 427 April 2023Option to Purchase Common Stock · traded 27 April 2023 · filed 27 April 2023
- was granted 200,000 shares of Provention Bio (a derivative holding)SEC Form 411 January 2023Stock Option (right to buy) · traded 10 January 2023 · filed 11 January 2023
- was granted 90,000 shares of Provention Bio (a derivative holding)SEC Form 423 November 2022Stock Option (right to buy) · traded 22 November 2022 · filed 23 November 2022
- was granted 60,000 shares of Provention Bio (a derivative holding)SEC Form 424 March 2022Stock Option (right to buy) · traded 22 March 2022 · filed 24 March 2022
- was granted 145,000 shares of Provention Bio (a derivative holding)SEC Form 420 January 2022Stock Option (right to buy) · traded 18 January 2022 · filed 20 January 2022
- was granted 30,000 shares of Provention Bio (a derivative holding)SEC Form 45 August 2021Stock Option (right to buy) · traded 3 August 2021 · filed 5 August 2021
- was granted 139,500 shares of Provention Bio (a derivative holding)SEC Form 414 May 2021Stock Option (right to buy) · traded 12 May 2021 · filed 14 May 2021
- was granted 300,000 shares of Provention Bio (a derivative holding)SEC Form 43 August 2020Stock Option (right to buy) · traded 3 August 2020 · filed 3 August 2020
- was granted 35,000 shares of Axcella Health (a derivative holding)SEC Form 420 December 2019Stock Option (Right to Buy) · traded 18 December 2019 · filed 20 December 2019
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.